Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1805 results
June 2020
-
Media ReleaseNovartis discontinues hydroxychloroquine clinical trial based on slow enrollment, remains committed to pandemic research effortsStudy discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
-
Streamlining systems to respond to COVID-19
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
-
Featured NewsWorld Sickle Cell Day 2020
Standing by people with sickle cell disease and their families
-
Media ReleaseNovartis expands Africa Sickle Cell Disease program to Uganda and TanzaniaNew collaborations aim to reduce the burden of sickle cell disease (SCD) in East Africa and improve access to high quality care Program continues progress in Ghana with more than 2000 patients…
-
Key ReleaseNovartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritisFDA approval for Cosentyx® is based on the Phase III PREVENT trial, demonstrating efficacy in active non-radiographic axial spondyloarthritis (nr-axSpA), which is part of the axial…
-
Featured NewsDay of the African Child 2020
COVID-19 is disrupting Africa’s health services – potentially undermining decades of progress on child health.
-
StatementStanding for Racial Equity and Justice as One Novartis
-
Media ReleaseUS FDA approves updated Novartis Beovu® label, to include additional safety informationNovartis worked with US Food and Drug Administration (FDA) to update Beovu (brolucizumab) prescribing information to guide healthcare professionals in their treatment of wet AMD patients1 The…
-
Media ReleaseNovartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthmaOnce-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving…
-
Media ReleaseNovartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritisPhase III PREVENT data show Cosentyx® 150 mg provided significant and sustained improvement in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) up to Week 521 nr-axSpA…
-
Featured NewsPride @ Novartis 2020 – inspired to make a difference
Together in spirit. Find out how our associates all over the world are joining together to make a difference as we celebrate Pride 2020.
-
Media ReleaseNovartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosisBasel, June 2, 2020 — Novartis today announced that it has received notice from the US Food and Drug Administration (FDA) that the agency has extended its review of the Supplemental Biologics…
Pagination
- ‹ Previous page
- 1
- …
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- …
- 151
- › Next page